Eli Lilly Acquires Verve Therapeutics to Enhance Cardiovascular Portfolio

Eli Lilly has acquired gene-editing startup Verve Therapeutics for approximately $1 billion, expanding its portfolio to include innovative treatments for cardiovascular disease. This acquisition allows Lilly to leverage Verve's gene-editing expertise to develop therapies targeting genetic causes of heart disease, which remains a major global health issue.

Under the deal, Lilly will purchase all outstanding shares of Verve at $10.50 each, with an additional $300 million in milestone payments based on clinical progress. This move aligns with Lilly’s strategy to integrate cutting-edge gene-editing technologies, like CRISPR and base editing, into its treatment offerings for genetic diseases.

Verve's therapies aim to directly address genetic mutations causing cardiovascular diseases, offering a new approach to treatment by potentially correcting these defects at the DNA level. Lilly’s acquisition underscores its commitment to advancing gene-editing solutions to meet unmet medical needs.

The addition of Verve to Lilly’s portfolio strengthens its position in the gene-editing space and complements its established strengths in diabetes, oncology, and immunology. The acquisition could lead to breakthrough treatments for cardiovascular disease, providing new hope for patients.

With this acquisition, Eli Lilly is poised to lead the way in developing transformative gene therapies for cardiovascular conditions, signaling a new era in genetic medicine.

---

Created: June 20th, 2025

Citations:

Hart, C. (2025, June 17). Eli Lilly to acquire Verve Therapeutics for up to $1.3 billion. The Wall Street Journal. https://www.wsj.com/articles/eli-lilly-to-acquire-verve-therapeutics-for-up-to-1-3-billion